• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    10/3/22 8:48:55 AM ET
    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • LogicBio Therapeutics (NASDAQ:LOGC) shares moved upwards by 641.3% to $2.02 during Monday's pre-market session. The company's market cap stands at $66.5 million.
    • Myovant Sciences (NYSE:MYOV) stock moved upwards by 31.68% to $23.65. The company's market cap stands at $2.2 billion.
    • Acorda Therapeutics (NASDAQ:ACOR) shares moved upwards by 20.36% to $0.36. The company's market cap stands at $8.7 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares moved upwards by 20.12% to $0.47. The company's market cap stands at $15.3 million.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock rose 19.79% to $0.88. The market value of their outstanding shares is at $40.1 million.
    • GBS (NASDAQ:GBS) stock moved upwards by 19.04% to $0.5. The company's market cap stands at $7.4 million.

    Losers

    • Clene (NASDAQ:CLNN) stock declined by 13.2% to $2.43 during Monday's pre-market session. The market value of their outstanding shares is at $154.3 million.
    • Ainos (NASDAQ:AIMD) stock fell 9.53% to $1.71. The company's market cap stands at $33.3 million.
    • Alector (NASDAQ:ALEC) stock declined by 8.04% to $8.7. The company's market cap stands at $718.3 million.
    • Orchard Therapeutics (NASDAQ:ORTX) shares declined by 8.0% to $0.46. The market value of their outstanding shares is at $58.1 million.
    • GreenLight Biosciences (NASDAQ:GRNA) shares declined by 7.33% to $2.15. The company's market cap stands at $264.8 million.
    • Medigus (NASDAQ:MDGS) stock declined by 7.08% to $0.51. The company's market cap stands at $12.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIMD
    $ALEC
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    Alector Inc.
    $ALEC
    10/22/2025$1.50Outperform → Neutral
    Mizuho
    Alector Inc.
    $ALEC
    10/22/2025Buy → Hold
    TD Cowen
    Alector Inc.
    $ALEC
    10/22/2025Overweight → Neutral
    Cantor Fitzgerald
    Alector Inc.
    $ALEC
    10/22/2025Outperform → Mkt Perform
    William Blair
    Alector Inc.
    $ALEC
    10/22/2025Buy → Neutral
    BTIG Research
    Alector Inc.
    $ALEC
    7/28/2025$3.50Neutral → Outperform
    Mizuho
    Alector Inc.
    $ALEC
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    Alector Inc.
    $ALEC
    12/16/2024$4.00Buy → Hold
    Stifel
    More analyst ratings

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    SEC Filings

    View All

    Amendment: ContextLogic Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K/A - ContextLogic Holdings Inc. (0002064307) (Filer)

    3/5/26 4:47:03 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form S-8 filed by ContextLogic Inc.

    S-8 - ContextLogic Holdings Inc. (0002064307) (Filer)

    3/5/26 4:25:29 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 10-K filed by ContextLogic Inc.

    10-K - ContextLogic Holdings Inc. (0002064307) (Filer)

    3/5/26 4:20:56 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Wong-Sarad Grace sold $7,012 worth of shares (3,367 units at $2.08), decreasing direct ownership by 3% to 107,465 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    3/3/26 6:01:23 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Principal Accounting Officer Wong-Sarad Grace sold $17,138 worth of shares (8,071 units at $2.12), decreasing direct ownership by 7% to 110,832 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    3/3/26 4:05:22 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Rosenthal Arnon sold $173,822 worth of shares (81,864 units at $2.12), decreasing direct ownership by 3% to 2,338,176 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    3/3/26 4:05:20 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bobbili Raja bought $12,311,558 worth of shares (1,758,794 units at $7.00) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    2/26/26 8:42:27 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Large owner Abrams Capital Management, L.P. bought $12,311,558 worth of shares (1,758,794 units at $7.00) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    2/26/26 8:37:36 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Abrams David C bought $12,311,558 worth of shares (1,758,794 units at $7.00) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    2/26/26 8:36:32 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial Results

    OAKLAND, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. Company Update Subsequent to the end of the fourth quarter 2025, the Company completed the acquisition of US Salt Parent Holdings, LLC and its subsidiaries (together, "US Salt"), marking a pivotal milestone in ContextLogic's evolution into a business ownership platform. The Company remains focused on identifying and pursuing additional acquisitions of businesses that are niche, competitively advantaged, and built for long-duration value creation. Four

    3/5/26 4:10:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    ContextLogic Completes $907.5 Million Acquisition of US Salt, Marking Transformation into Business Ownership Platform

    OAKLAND, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced the successful completion of its acquisition of US Salt Parent Holdings, LLC and its subsidiaries (collectively, "US Salt") from private equity funds managed by Emerald Lake Capital Management ("Emerald Lake") in a transaction that valued US Salt at an enterprise value of approximately $907.5 million (the "Transaction"). The closing of this Transaction marks a transformational milestone for ContextLogic, completing its evolution from an e-commerce company into a distinctive business ownership platform focused on owning niche, competiti

    2/26/26 4:45:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc.

    2/25/26 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by Mizuho with a new price target

    Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $1.50

    10/22/25 7:10:52 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by TD Cowen

    TD Cowen downgraded Alector from Buy to Hold

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Alector from Overweight to Neutral

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His

    12/12/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rishi Bajaj, Founder and CIO of Altai Capital Management and CEO of ContextLogic Inc., Joins Digimarc's Board of Directors

    Bajaj brings broad financial and strategic experience to Digimarc Board as the company builds the trust layer for the modern world. Digimarc Corporation (NASDAQ:DMRC), a pioneer in digital watermarking technologies, today announced the appointment of Rishi Bajaj, founder and CIO of private investment firm Altai Capital Management, L.P. ("Altai") and CEO of ContextLogic Inc., to its Board of Directors. Bajaj's qualifications to serve on the board include extensive investment management, operational, and board experience, particularly in the technology sector. Alongside Bajaj's appointment, Digimarc has entered into a cooperation agreement with Bajaj and Altai Capital Management, L.P.. Th

    7/29/25 8:00:00 AM ET
    $DMRC
    $LOGC
    $MOBL
    EDP Services
    Technology
    Catalog/Specialty Distribution
    Consumer Discretionary

    ContextLogic Appoints Finance Executive Michael Scarola as New Chief Financial Officer

    OAKLAND, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTC:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced the appointment of Michael Scarola as Chief Financial Officer, effective June 30, 2025. "We are thrilled to appoint Michael Scarola to the position of Chief Financial Officer. This appointment reflects our strategy to streamline our business as much as possible while we pursue value maximation through organic growth and accretive acquisitions." said Rishi Bajaj, Chief Executive Officer. Mr. Scarola currently serves as the Chief Financial Officer, Chief Operating Officer, and Chief Compliance Officer of Altai Capital, and has developed a wide a

    6/25/25 4:30:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Financials

    Live finance-specific insights

    View All

    ContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial Results

    OAKLAND, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. Company Update Subsequent to the end of the fourth quarter 2025, the Company completed the acquisition of US Salt Parent Holdings, LLC and its subsidiaries (together, "US Salt"), marking a pivotal milestone in ContextLogic's evolution into a business ownership platform. The Company remains focused on identifying and pursuing additional acquisitions of businesses that are niche, competitively advantaged, and built for long-duration value creation. Four

    3/5/26 4:10:00 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    ContextLogic to Acquire US Salt from Emerald Lake in $907.5 Million Transaction, Creating New Business Ownership Platform in Partnership with Abrams Capital and BC Partners Credit

    Marks the first step in building ContextLogic into a differentiated business ownership platform. ContextLogic will be focused on owning niche, competitively-advantaged, long-duration businesses run by world-class management teams.US Salt, the first such acquisition, is a 132-year old business producing high-purity evaporated salt products for recession-resilient end markets. Led by a management team with 25+ year record of value creation, US Salt has consistently delivered strong revenue growth, robust margins, and high cash flow generation. ContextLogic shareholders will have the opportunity to commit additional capital in the transaction via a rights offering, which has been fully backstop

    12/8/25 7:30:17 AM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIMD
    $ALEC
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care